Olema Director Gorjan Hrustanovic Resigns From Board; Prakash Raman Takes His Two Committee Seats
An 8-K says the resignation followed no disagreement with Olema over operations, policies or practices.
Olema Pharmaceuticals director Dr. Gorjan Hrustanovic told the company on Monday that he is resigning from its board, effective Wednesday, according to an 8-K the company filed Thursday. The board then named Dr. Prakash Raman to the two committees Hrustanovic leaves.
What the 8-K says
The filing falls under Item 5.02, the section of the 8-K that covers departures of directors and certain officers. It says Hrustanovic gave notice of his decision on Monday, and the resignation takes effect Wednesday.
He also left two board committees: the Compensation Committee and the Science and Technology Committee.
The company states that the resignation "was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices." Olema also thanked him for his service and contributions to the company and the board.
The 8-K does not name the reason he is leaving.
Who fills the committee seats
On Thursday, the board acted on a recommendation from its Nominating and Corporate Governance Committee. It appointed Raman to both the Compensation Committee and the Science and Technology Committee, each effective Thursday.
That means both of Hrustanovic's committee seats were refilled the day after his resignation took effect. The filing describes the appointments only as committee assignments for Raman.
Sean Bohen, M.D., Ph.D., Olema's president and chief executive officer, signed the filing on Thursday.
What it changes
The board loses one director as of Wednesday. The filing does not say whether the seat will be filled or whether the board's size will change.
The company's own statement is the only account of the departure in the filing, and it rules out a dispute over how Olema is run. Olema's shares trade on the Nasdaq Global Select Market under the symbol OLMA.
The next filing to check is any further 8-K from Olema under Item 5.02, which is where a replacement director or a change in board size would be reported.
Sources
- 8-K Filing — Olema Pharmaceuticals, Inc. (OLMA) — SEC EDGAR